期刊文献+

霍乱毒素联合弓形虫排泄-分泌抗原鼻内免疫小鼠诱导的GALT和NALT黏膜免疫应答 被引量:2

Intranasal immunization with cholera toxin and excreted-secreted antigens of Toxoplasma gondii induces an immune response at both NALT and GALT mucosal sites in mice
原文传递
导出
摘要 目的观察霍乱毒素(CT)联合弓形虫排泄-分泌抗原(ESA)鼻内免疫小鼠诱导的肠相关淋巴组织(GALT)和鼻相关淋巴组织(NALT)黏膜部位的免疫应答。方法将48只5~6周龄BABL/c小鼠随机均分为3组,分别用PBS、ESA和CT+ESA滴鼻免疫小鼠2次,间隔2周。末次免疫后14d,处死小鼠,ELISA测定小鼠粪便和鼻咽冲洗液sIgA抗体水平;计数派伊尔淋巴集结(PP)、肠上皮淋巴细胞(IEL)、NALT和鼻通道(NC)淋巴细胞数,免疫细胞化学法检测CD4^+、CD8^+T细胞亚群水平。结果免疫后14d,CT+ESA组小鼠鼻咽冲洗液和粪便sIgA水平显著高于ESA组和PBS组(P〈0.01);CT+ESA和ESA组小鼠GALT部位的PP淋巴细胞显著增生,主要以CD4^+T细胞为主;而IEL以CD8^+T细胞增生为主,CD4^+/CD8^+比值降低(P〈0.05)。CT+ESA NALT内淋巴细胞明显增生。CT+ESA组NC淋巴细胞显著升高(P〈0.01),以CD4^+T细胞增生为主。结论CT佐剂联合ESA滴鼻免疫BALB/c小鼠可诱导GALT和NALT黏膜部位免疫应答。 Objective To study the immune response at mucosal sites, i.e. gut-associated lymphoid tissue (GALT) and nasal associated lymphoid tissue (NALT), after intranasal immunization with cholera toxin (CT) and excreted-secreted antigens (ESA) of Toxoplasma gondii. Methods BALB/c mice were randomly divided equally into three groups. Mice were intranasally immunized with PBS 20 μl, ESA 20 μg, or 1.0 μg CT + 20μg ESA per mouse twice at an interval of two weeks. Mice were sacrificed on day 14 after final immunization. Levels of sIgA antibodies in feces and nasopharynx washes were detected by ELISA. Lymphocytes in Peyer's patches (PP), intraepithelial lymphocytes (IEL), NALT, and nasal passages (NC) were isolated and counted. The percentage of CD4^+ and CD8^+ T cells was determined by immunocytochemistry. Results The levels of sIgA antibodies in feces and nasopharynx washes of immunized mice in the CT+ ESA group were higher than levels in PBS and ESA groups on day 14 after immunization (P〈0.05). Lymphocytes in NALT increased significantly (P〈0.05) in the CT group after immunization. CD4^+ and CD8^+ T cell counts were higher than those of the PBS group (P〈0.01), while the ratio of CD4^+ and CD8^+ T cells decreased (P〈0.05). Lymphocytes in NC and PP increased (P〈0.01) with mainly CD4^+ T cells increasing (P〈0.01). With IEL, primarily the CD8+ T count increased significantly (P〈0.01), and the ratio of CD4^+ and CD8^+ T cells was significantly lower (P〈0. 05). Conclusion This study indicated that intranasal immunization with cholera toxin and ESA of T. gondii can effectively induce immune response in both NALT and GALT.
出处 《中国病原生物学杂志》 CSCD 2011年第4期265-268,259,共5页 Journal of Pathogen Biology
基金 国家自然科学基金项目(No.81071374)
关键词 刚地弓形虫 霍乱毒素 排泄-分泌抗原 黏膜免疫 肠相关淋巴组织 鼻相关淋巴组织 Toacoplasma gondii cholera toxin excreted-secreted antigens mucosal immunity gut associated lymphoid tissue (GALT) nasal associated lymphoid tissue (NALT)
  • 相关文献

参考文献21

  • 1Holmgren J, Czerkinsky C. Mucosal immunity and vaccines [J]. Nat Med, 2005, 11(4 Suppl).:S45-53.
  • 2韩剑峰,殷国荣.弓形虫诱导的黏膜细胞免疫应答研究进展[J].免疫学杂志,2003,19(5):401-403. 被引量:14
  • 3弓鸿飞,殷国荣.肠上皮内淋巴细胞抗弓形虫感染的免疫功能研究进展[J].国际医学寄生虫病杂志,2006,33(4):202-205. 被引量:2
  • 4Stanley AC, Huntley JF, Jeffrey M, et al. Characterization of o- vine nasal associated lymphoid tissue and identification of M cells in the overlying folllcle-associated epithelium [J]. Comp Pathol, 2001, 125(4): 262-70.
  • 5Heritage PL, Underdown BJ, Larry Arsenault A, et al. Compar- ison of murine nasal-associated lymphoid tissue and Peyer's pat- ches [J]. Respir Crit Care Med, 1997, 156(4):1256-62.
  • 6Dietrich G, Griot-Wenk M, Metealfe IC, et al. Experience with registered mucosal vaccines [J]. Vaccine, 2003, 21(7-8): 678 -3.
  • 7Davis SS. Nasal vaccines [J]. Adv Drug Deliv Rev, 2001, 51(1 -3): 21-42.
  • 8Byun Y, Ohmura M, Fujihashi K, et al. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies [J]. Vac- cine, 2001, 19(15-16): 2061-70.
  • 9Kasper L, Courret N, Darche S, et al. Toxoplasma gondii and mucosal immunity[J]. Int J Parasitol, 2004, 34(3): 401-9.
  • 10刘娟娟,殷国荣,管志玉,石蓉,张宇斌,孟晓丽.小鼠腹水中弓形虫排泄分泌抗原鼻内免疫小鼠诱导的免疫应答[J].中国病原生物学杂志,2007,2(2):110-114. 被引量:6

二级参考文献100

共引文献40

同被引文献81

  • 1刘晋平,殷国荣,孟晓丽,杨亚波,刘红丽.弓形虫可溶性速殖子抗原和霍乱毒素滴鼻免疫小鼠诱导的鼻通道细胞免疫应答[J].热带医学杂志,2006,6(7):758-760. 被引量:3
  • 2卫大英,马名驹,马志凌,边仕超,马兆瑾,肖林,潘璐,毛木呷.彝族健康人群外周血T淋巴细胞正常参考值研究[J].现代预防医学,2007,34(3):416-418. 被引量:7
  • 3Lowenadler B, Lycke N. Fusion proteins with heterologous T helper epitopes. Recombinant E. coli heat-stable enterotoxin proteins [J]. Int RevImmunol, 1994, 11(2): 103-11.
  • 4Agren LC, Ekman L, Lowenadler B, et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A subunit [J].J lm munol, 1997, 158(8): 3936-46.
  • 5Agren I.C, Ekman L, Lowenadler B, et al. Adjuvanticity of the cholera toxin Al-based fusion protein, CTA1 DD, is critically dependent on the ADP-rihosyltransferase and Ig-binding activity [J]. J Immunol, 1999, 162(4): 2432-40.
  • 6Agren L, Sverremark E, Ekman L, et al. The ADP-ribosylating CTA1-DD adjuvant enhances T-cell dependent and independent responses by direct action on B cells involving anti apoptotie Bcl 2- and germinal center promoting effects [J]. J Immunol, 2000,164(12): 6276-86.
  • 7Sundling C, SchoK, Morner A, et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization [J]. Gen Virol, 2008, 89(Pt 12):2954-64.
  • 8Dell K, Koesters R, Linnebacher M, et al. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels [J]. Vaccine, 2006, 24(13): 2238-47.
  • 9Eliasson DG, El Bakkouri K, Schon K, et al. CTA1-M2e DD: a novel mucosM adjuvant targeted influenza vaccine [J]. Vaccine, 2008, 26(9): 1243-52.
  • 10Holmgren J, Czerkinsky C. Mucosal immunity and vaccines [J]. Nat Med, 2005, 11 (4): S45-S53.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部